| Firm | Analyst | Phone | |
|---|---|---|---|
| Arete Research | Pierre-Marie D’Ornano | p.dornano@arete.net | +44 (0)20 7959 1319 |
| ATB Capital Markets | Martin Toner | mtoner@atb.com | 647 776-8241 |
| B Riley Securities | Nicholas Giles | ngiles@brileyfin.com | 703 312-1815 |
| Bernstein | Gautam Chhugani | Gautam.chhugani@bernsteinsg.com | +91 226-842-1416 |
| BofA Securities | Michael Funk | michael.j.funk@bofa.com | 646 855 5664 |
| Cantor Fitzgerald | Brett Knoblauch | Brett.Knoblauch@cantor.com | 212 610-2221 |
| Chardan Capital Markets | Bill Papanastasiou | pmeeks@freedomcapmkts.com | 646 465 9000 |
| Citi | Michael Rollins | michael.rollins@citi.com | 202 816-1116 |
| Citizens JMP | Greg P. Miller | Gregory.miller@citizensbank.com | 212 699-2917 |
| Clear Street | Brian Dobson | bdobson@clearstreet.io | 646 789-4717 |
| Compass Point Research | Michael Donovan | mdonovan@compasspointllc.com | 202 540-7306 |
| Jefferies | Jonathan Petersen | jpetersen@jefferies.com | 212 284-1705 |
| Keefe, Bruyette & Woods (KBW) | Stephen Glagola | glagolas@kbw.com | +1 415 527 7340 |
| Lucid Capital Markets | Darren Aftahi | daftahi@roth.com | 212 306-2700 |
| Morgan Stanley | Stephen Calder Byrd | stephen.byrd@morganstanley.com | 212 761-3865 |
| Needham & Company | John Todaro | jtodaro@needhamco.com | 212 705-0446 |
| Northland Securities | Mike Grondahl | mgrondahl@northlandcapitalmarkets.com | 612 851-4973 |
| Oppenheimer | Timothy Horan | Timothy.horan@opco.com | 201 264-5080 |
| Rosenblatt Securities | Chris Brendler | cbrendler@rblt.com | 212 607-3124 |
| Wells Fargo Securities | Eric Luebchow | eric.luebchow@wellsfargo.com | 312 630 2386 |
| William Blair | Jed Dorsheimer | jeddorsheimer@williamblair.com | 617 235 7555 |
TeraWulf Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding TeraWulf Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of TeraWulf Inc. or its management. TeraWulf Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.